Juan Li

机构：Sichuan Cancer Hospital · ORCID：0000-0002-6141-0762

发表论文 43 篇 · 总被引 2187 次 · h-index 22

代表论文

• Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12) (2021 · Journal of Thoracic Oncology · 被引 324)
• AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations (2022 · Journal of Clinical Oncology · 被引 294)
• Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study (2021 · Journal of Thoracic Oncology · 被引 153)
• m6A modification of lncRNA ABHD11-AS1 promotes colorectal cancer progression and inhibits ferroptosis through TRIM21/IGF2BP2/ FOXM1 positive feedback loop (2024 · Cancer Letters · 被引 46)
• Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety From a Phase 2 Study in People’s Republic of China (2022 · Journal of Thoracic Oncology · 被引 35)
• Safety and activity of WX-0593 (Iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion trial (2022 · Signal Transduction and Targeted Therapy · 被引 35)